Company: CRL
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001100682-25-000034
Chunk: 27

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 2
Chunk 27
---
 asset impairment, accelerated depreciation, and other site consolidation charges. During fiscal year 2023, we began taking restructuring actions as a result of these emerging business trends. We incurred restructuring charges of $32.2 million and $56.0 million, during the three and six months ended June 28, 2025, respectively, and $107.0 million and $29.7 million during fiscal 2024 and fiscal 2023, respectively. We expect that these effectuated actions, as well as other upcoming planned actions designed to optimize our global footprint to drive greater operating efficiency, will result in approximately $225 million of cost savings on an annualized basis, of which approximately $175 million will impact fiscal year 2025.

27 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Results of Operations

Consolidated Results of Operations and Liquidity

Revenue for three months ended June 28, 2025 increased $6.0 million, or 0.6%, to $1,032.1 million compared to $1,026.1 million in the corresponding period in 2024. Revenue for six months ended June 28, 2025 decreased $21.4 million, or 1.0%, to $2,016.3 million compared to $2,037.7 million in the corresponding period in 2024. The increase in revenue for the three months ended June 28, 2025 was primarily attributable to our Manufacturing and RMS businesses driven by demand, partially offset by declines in our DSA business, which experienced lower volume driven by continued cautious client spending as a result of the demand environment when compared to the corresponding period in 2024. The decrease in revenue for the six months ended June 28, 2025 was driven by declines in our DSA business driven by the same market dynamics discussed above when compared to the corresponding period in 2024.

For the three months ended June 28, 2025, our operating income and operating income as a percentage of revenue were $100.1 million and 9.7% respectively, compared to $151.7 million and 14.8% respectively, in the corresponding period of 2024. For the six months ended June 28, 2025, our operating income and operating income as a percentage of revenue were $174.8 million and 8.7% respectively, compared to $277.6 million and 13.6% respectively, in the